Toxicity from treatment of neuroblastoma with 131 I-meta-iodobenzylguanidine

Show simple item record

dc.contributor.author Mallette, Shirley A. en_US
dc.contributor.author Carey, James E. en_US
dc.contributor.author Hutchinson, Raymond J. en_US
dc.contributor.author Shapiro, Brahm en_US
dc.contributor.author Johnson, Jon W. en_US
dc.contributor.author Wieland, Donald M. en_US
dc.contributor.author Sisson, James C. en_US
dc.date.accessioned 2006-09-11T18:15:05Z
dc.date.available 2006-09-11T18:15:05Z
dc.date.issued 1988-09 en_US
dc.identifier.citation Sisson, James C.; Hutchinson, Raymond J.; Carey, James E.; Shapiro, Brahm; Johnson, Jon W.; Mallette, Shirley A.; Wieland, Donald M.; (1988). "Toxicity from treatment of neuroblastoma with 131 I-meta-iodobenzylguanidine." European Journal of Nuclear Medicine 14 (7-8): 337-340. <http://hdl.handle.net/2027.42/46827> en_US
dc.identifier.issn 1619-7089 en_US
dc.identifier.issn 0340-6997 en_US
dc.identifier.uri http://hdl.handle.net/2027.42/46827
dc.identifier.uri http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=3181182&dopt=citation en_US
dc.description.abstract Toxic effects from 131 I-meta-iodobenzylguanidine ( 131 I-MIBG) treatments of neuroblastoma in six patients were recorded. The toxicity was largely confined to the hematologic system where circulating leukocytes and platelets regularly declined after each dose of 131 I-MIBG; the values reached nadirs between three and seven weeks and recovered slowly over subsequent weeks. Prior bone marrow transplantation and infiltration of bone marrow by neuroblastoma appeared to make the hematologic system more vulnerable to the radiation. Dosimetry revealed greater absorbed radiation by the whole body than by the blood and bone marrow. These observations are explained by a relatively rapid exit of 131 I-MIBG from the blood to other tissues (but not to the bone marrow). Since treatment of an aggressive and lethal tumor such as neuroblastoma should be pushed to a degree of toxicity, careful dosimetry in each case will be necessary as a guide to reach the point of maximally tolerable toxicity. en_US
dc.format.extent 424961 bytes
dc.format.extent 3115 bytes
dc.format.mimetype application/pdf
dc.format.mimetype text/plain
dc.language.iso en_US
dc.publisher Springer-Verlag en_US
dc.subject.other Imaging / Radiology en_US
dc.subject.other Meta-iodobenzylguanidine en_US
dc.subject.other Neuroblastoma en_US
dc.subject.other Nuclear Medicine en_US
dc.subject.other Medicine & Public Health en_US
dc.subject.other Radiation Toxicity en_US
dc.subject.other Bone Marrow en_US
dc.title Toxicity from treatment of neuroblastoma with 131 I-meta-iodobenzylguanidine en_US
dc.type Article en_US
dc.subject.hlbsecondlevel Radiology en_US
dc.subject.hlbsecondlevel Physics en_US
dc.subject.hlbsecondlevel Biological Chemistry en_US
dc.subject.hlbtoplevel Science en_US
dc.subject.hlbtoplevel Health Sciences en_US
dc.description.peerreviewed Peer Reviewed en_US
dc.contributor.affiliationum Division of Nuclear Medicine, Department of Internal Medicine, The University of Michigan Medical Center, 48109, 0028, Ann Arbor, MI, USA en_US
dc.contributor.affiliationum Division of Nuclear Medicine, Department of Internal Medicine, The University of Michigan Medical Center, 48109, 0028, Ann Arbor, MI, USA en_US
dc.contributor.affiliationum Division of Hematology-Oncology, Department of Pediatrics, The University of Michigan Medical Cener, 48109, 0028, Ann Arbor, MI, USA en_US
dc.contributor.affiliationum Division of Nuclear Medicine, Department of Internal Medicine, The University of Michigan Medical Center, 48109, 0028, Ann Arbor, MI, USA en_US
dc.contributor.affiliationum Division of Nuclear Medicine, Department of Internal Medicine, The University of Michigan Medical Center, 48109, 0028, Ann Arbor, MI, USA en_US
dc.contributor.affiliationum Division of Nuclear Medicine, Department of Internal Medicine, The University of Michigan Medical Center, 48109, 0028, Ann Arbor, MI, USA en_US
dc.contributor.affiliationum Division of Nuclear Medicine, Department of Internal Medicine, The University of Michigan Medical Center, 48109, 0028, Ann Arbor, MI, USA en_US
dc.contributor.affiliationumcampus Ann Arbor en_US
dc.identifier.pmid 3181182 en_US
dc.description.bitstreamurl http://deepblue.lib.umich.edu/bitstream/2027.42/46827/1/259_2004_Article_BF00254379.pdf en_US
dc.identifier.doi http://dx.doi.org/10.1007/BF00254379 en_US
dc.identifier.source European Journal of Nuclear Medicine en_US
dc.owningcollname Interdisciplinary and Peer-Reviewed
 Show simple item record

This item appears in the following Collection(s)


Search Deep Blue

Advanced Search

Browse by

My Account

Information

Available Now


MLibrary logo